Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
125 hedge funds and large institutions have $480M invested in Achillion Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 41 increasing their positions, 41 reducing their positions, and 17 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
63% more call options, than puts
Call options by funds: $1.89M | Put options by funds: $1.16M
3.62% more ownership
Funds ownership: 74.48% → 78.1% (+3.6%)
3% more capital invested
Capital invested by funds: $467M → $480M (+$12.2M)
0% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 41
3% less funds holding
Funds holding: 129 → 125 (-4)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$27.7M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$9.49M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.25M |
| 4 |
AC
Armistice Capital
New York
|
+$4.53M |
| 5 |
AG
Artal Group
Luxembourg
|
+$4.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$16M |
| 2 |
Millennium Management
New York
|
-$11.6M |
| 3 |
SAM
Senzar Asset Management
New York
|
-$4.97M |
| 4 |
Goldman Sachs
New York
|
-$4.03M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.41M |
ACHN Hedge Fund Activity: Q3 2017 in Review
125 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q3 2017, worth a combined $480M — up 2.6% from $467M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ACHN and 14 opened new positions — a net loss of 3 holders — while 41 trimmed existing stakes and 41 added.
The largest buyer was RTW Investments, adding an estimated $27.7M. The largest seller was BVF Inc, exiting entirely with an estimated $16M sold.
- 125 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q3 2017, down from 129 in Q2 2017.
- Funds reported $480M of Achillion Pharmaceuticals stock for Q3 2017, up 2.6% quarter-over-quarter.
- 14 funds opened new Achillion Pharmaceuticals positions in Q3 2017 and 17 closed out, a net change of -3 holders.
- The largest Achillion Pharmaceuticals buyer in Q3 2017 was RTW Investments, an estimated $27.7M added.
- The largest Achillion Pharmaceuticals seller in Q3 2017 was BVF Inc, an estimated $16M sold.
Based on aggregated 13F filings for Q3 2017.